In 1960's, with successful renal transplantations, acute rejection became to be a serious problem for graft survival. From 1965 to 2010, with the introduction of new immunosuppressant agents such as cyclosporine, mycophenolate mofetile and tacrolimus, the acute rejection rates declined from 80% to 10% . There is an ongoing gradual improvement in allograft survival. Use of therapeutic plasma exchange (TPE) is not evidence based treatment, but TPE is necessary for pre-and also post transplantation in patients with donor specific antibody. TPE is also a main treatment for antibody mediated rejection, but in clinical practice the duration and frequency of TPE and individual difference of antibody production is unclear. There is a requirement for more specific antibody elimination. Further randomized controlled studies are needed to elucidate TPE use before and after kidney transplantation.
Introduction
In 1960's, with successful renal transplantations, acute rejection became to be a serious problem for graft survival. From 1965 to 2010, with the introduction of new immunosuppressant agents such as cyclosporine, mycophenolate mofetile and tacrolimus, the acute rejection rates declined from 80% to 10%. There is an ongoing gradual improvement in allograft survival (1) .
Pretransplant presence of anti-HLA antibody is a risk factor for acute antibody mediated rejection (AMR) and worse prognosis in United States. The United States Renal Data System (USRDS) data shows that 22% of the waiting list patients have preformed anti-HLA antibodies, which preclude these patients from kidney transplantation. Anti-HLA antibody prolongs the waiting time for deceased organ transplantation, reduces transplantation and increases the rate of death (1) . Any individual, who has experienced sensitizing events, such as transfusion, pregnancy or previous transplant, is at risk for developing anti-HLA antibodies. So, it is important to detect and identify these antibodies prior to receiving an organ for transplant or re-transplant.
Anti HLA antibodies can be detected by ELISA, Luminex (panel reactive antibodies) and lymphocyte crossmatch (LCM) tests. Panel reactive antibodies (PRA) are a pool of well-characterized panel cells in order to detect alloantibody reactivity and specificity in patients' sera and represent the percentage of positive cells. For LCM, donor B and T cells incubated with patient's serum and then complement added. If T cell lysis occurs there is a Class I anti-HLA donor specific antibody, if B cell lysis occurs there is a Class II anti-HLA donor specific antibody. Positive crossmatch test is a contraindication for transplantation. Positive crossmatch carries high risk of (80%) immediate graft loss (2) .
Hyperacute AMR occurs when there are high titers of preformed donor specific antibody (DSA). Graft loss occurs within 24 hours post-transplantation. Accelerated AMR happens after 24 hours of transplantation. There is low titer of DSA and rejection does not respond to standard therapy. Acute AMR occurs due to 'de novo' production of DSA or post-desensitization, restart of DSA production. Rejection occurs within 1 week to 3-6 months post-transplant and there is no response to standard therapy. Late or chronic AMR is the result 9 Disease and Molecular Medicine -www.dismolmed.org Çelebi & Keven of 'de novo' production of DSA. It usually happens 1 year post-transplant. There are few symptoms but the course is progressive and the prognosis is poor. Response to standard therapy is insufficient.
AMR can be diagnosed, when there is graft dysfunction and biopsy shows typical histopathological findings and peritubular C4d deposits and presence of DSA (3). Prognosis is worse comparing to acute cellular rejection (ACR). While 1-year graft loss rate is %3 in ACR, it is 27-40% in AMR (4).
Therapeutic plasma exchange
Plasmapheresis is a therapeutic option for AMR. Therapeutic plasma exchange (TPE, plasmapheresis) is an extracorporeal blood purification technique designed for the removal of large molecular weight substances from the plasma. Plasma and blood cells are separated by centrifugation or membrane filtration. The typical replacement fluids are fresh-frozen plasma, 5% albumin or other plasma derivatives and crystalloids (e.g., 0.9% saline, Ringer's lactate) (5, 6) . Double filtration plasmapheresis has lower risk of coagulopathy and hypogammaglobulinemia and requires less replacement fluid (7) .
The guidelines shows that TPE is second-line therapy for acute antibody mediated rejection and desensitization before kidney transplantation (8) . In AMR, TPE can be used to decrease DSA. The mean half-life of IgG in the blood is 23 days. IgG1 and G3 subtypes activate complement. G2 has low and G4 has no complement activation. If DSA is IgG, cessation of TPE after several procedures can result in pretreatment or even higher levels of IgG, especially if the patient is not on immunosuppressive therapy. As a result, a more rigorous regimen involving several TPE procedures and the institution of immunosuppressive therapy is required to significantly reduce IgG levels (9) .
If one assumes a negligible production rate of new immunoglobulin (due in part to concurrent immunosuppressive therapy) and that the rate of extravascular to intravascular equilibration is approximately 1 to 2 percent per hour, then five separate exchanges over 7 to 10 days is required to remove 90 percent of the total initial body immunoglobulin burden. So, additional treatments may be required if new antibody production occurs.
There are some studies showing the therapeutic effects of plasmapheresis in AMR. In a study five patients diagnosed AMR, treated with TPE (4-7 sessions), tacrolimus and mycophenolate mofetil. After 18 months, patient and allograft survival found to be 100% (10) . Three patients, who developed AMR after transplantation, successfully treated with plasmapheresis and IVIG (11) .
Six-teen patients with AMR treated with plasmapheresis and IVIG and their results were compared with the patients, who were treated for ACR. Results showed that AMR, when diagnosed early and treated aggressively with TPE and IVIG, carries a short-term prognosis that is similar to ACR (12) .
High DSA titers, rapid deterioration of renal function and presence of glomerular thrombi on biopsy are indications of plasmapheresis with IVIG and steroid as the treatment of AMR. Conventional therapies are not enough for inhibition of antibody production. Emerging therapies include bortezomib, a proteasome inhibitor, and eculizumab, an anti-C5 antibody. In several reports, bortezomib therapy resulted in prompt reversal of rejection, decreased titers of DSA, and improved renal allograft function. Eculizumab also reversed AMR and prevented its development in patients with high posttransplantation DSA levels (13) .
TPE can be used in sensitized patients to eliminate anti-HLA antibodies with or without IVIG (intravenous immunoglobuline). TPE administration is based on institutional experience (4 sessions before, 2-5 after). It depends the level of anti-HLA antibody titers or LCM results.
The studies show that there is a survival benefit for anti-HLA antibody positive patients with desensitization before kidney transplantation. Four patients, who treated for DSA before transplantation, plasmapheresis and IVIG showed promise for eliminating DSA preemptively among patients with low-titer positive antihuman globulin-enhanced, complement-dependent cytotoxicity cross-matches, allowing the successful transplantation of these patients using a live donor without any cases of hyperacute rejection (11) 
Conclusion
Use of TPE is not evidence based treatment, but TPE is necessary for pre-and also post transplantation in patients with DSA. TPE is also a main treatment for AMR, but in clinical practice the duration and frequency of TPE and individual difference of antibody production is unclear. There is a requirement for more specific antibody elimination. Further randomised controlled stud-Disease and Molecular Medicine -www.dismolmed.org Therapeutic plasmapheresis in kidney transplantation ies are needed to elucidate TPE use before and after kidney transplantation.
